Last reviewed · How we verify
Autologous Bone Marrow Mononuclear Cells
At a glance
| Generic name | Autologous Bone Marrow Mononuclear Cells |
|---|---|
| Also known as | BMMNCs |
| Sponsor | Vinmec Healthcare System |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction (NA)
- Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis (NA)
- Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia (PHASE2)
- Autologous BMMNCs Combined With Educational Intervention for ASD (PHASE2)
- Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina (PHASE2)
- CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial (NA)
- MIBG for Refractory Neuroblastoma and Pheochromocytoma (NA)
- CardiAMP™ Cell Therapy for Heart Failure Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: